Real-world progression-free survival in first-line advanced non-small cell lung cancer treated with immunotherapy-based regimens using a US dataset.

Waterhouse, David; Lam, Jenny; Betts, Keith A; Yin, Lei; Gao, Sophie; Yuan, Yong; Hartman, John; Rao, Sumati; Lubinga, Solomon; Stenehjem, David

Waterhouse, David; Lam, Jenny; Betts, Keith A; Yin, Lei; Gao, Sophie; Yuan, Yong; Hartman, John; Rao, Sumati; Lubinga, Solomon; Stenehjem, David.

Afiliação

Waterhouse D; OHC Cincinnati, Cincinnati, OH, USA.
Lam J; Bristol Myers Squibb, Lawrenceville, NJ, USA.
Betts KA; Analysis Group, Los Angeles, CA, USA.
Yin L; Analysis Group, Los Angeles, CA, USA.
Gao S; Analysis Group, Los Angeles, CA, USA.
Yuan Y; Bristol Myers Squibb, Lawrenceville, NJ, USA.
Hartman J; Bristol Myers Squibb, Lawrenceville, NJ, USA.
Rao S; Bristol Myers Squibb, Lawrenceville, NJ, USA.
Lubinga S; Bristol Myers Squibb, Lawrenceville, NJ, USA.
Stenehjem D; University of Minnesota, Minneapolis, MN, USA.

Data Brief ; 37: 107195, 2021 Aug.

Article em En | MEDLINE | ID: mdl-34169127

Palavras-chave

Immune checkpoint inhibitors; Immunotherapy; Non-small cell lung cancer; Real-world outcomes

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Data Brief Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google